At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 59 enrolled
Drug / intervention
Fluticasone propionate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study to Assess the Dose-response Curve of Intranasal Fluticasone Propionate (25, 50, 100 and 200 μg, Once Daily for 8 Days) in the Vienna Challenge Chamber for the Purpose of Investigating the Sensitivity
In Brief
A Phase 4 clinical trial evaluating Fluticasone propionate and Placebo for Rhinitis, Allergic, Perennial and Allergic Rhinitis. Completed, enrolled 59 participants across 1 site.
Detailed Summary
This is a single-centre, randomised, double-blind, four-period, incomplete block, crossover study, with 8 days repeat dosing of intranasal Fluticasone Propionate (25, 50, 100, 200ug) and/or placebo in the Vienna Challenge Chamber in subjects with allergic rhinitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis, Allergic, Perennial, Allergic Rhinitis
CountriesAustria
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
Primary CompletionJan 2008
First PostedFeb 2009
TodayJul 2026
First PostedFeb 23, 2009
Enrollment StartOct 1, 2007
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.4 years ago
Interventions
Fluticasone propionatedrug
Corticosteriod, with anti-inflammatory effects
Placebodrug
Placebo comparator